July 02, 2026
Rival pharmaceutical companies that squared off at the U.S. Supreme Court over antibody patents have jointly asked the full Federal Circuit to review an unrelated panel decision reviving migraine drug antibody patents.
June 17, 2026
Eli Lilly & Co. urged the full Federal Circuit Wednesday to review a panel ruling that upheld Teva's $177 million jury verdict on headache drug patents, arguing that the panel's decision runs afoul of the justices' Amgen holding and "opens a truck-sized hole in enablement and written description law."
April 16, 2026
The Federal Circuit ruled Thursday that a Massachusetts federal judge was wrong to overturn a $177 million jury verdict that Teva won against Eli Lilly & Co. on headache drug patents, finding that contrary to the judge's finding, the patents are not invalid.
April 22, 2024
Eli Lilly & Co. has urged the Federal Circuit to uphold a Massachusetts federal judge's decision that wiped out a $176.5 million verdict against it for infringing Teva migraine drug patents, saying the lower court correctly found the patent claims to be invalid.
February 05, 2024
Teva Pharmaceuticals has urged the Federal Circuit to reverse a Massachusetts federal judge's decision to toss out a $176.5 million migraine drug patent infringement verdict in its favor against Eli Lilly & Co., arguing that the judge's decision was based on "serious legal errors."